This was followed by the approval of evolocumab, whose effects on atherosclerosis were first demonstrated by the GLAGOV trial, showing that, in patients with angiographic coronary disease treated with statins, individuals taking the PCSK9 inhibitor evolocumab had significantly decreased LDL-C and a reduction in plaque atheroma volume compared to those on the placebo [68]. Here, PCSK9 is linked to atherosclerosis.